Publications by authors named "David C Dalgarno"

Claim this Profile
A
Author Correction: High-throughput prediction of protein conformational distributions with subsampled AlphaFold2.
Gabriel Monteiro da Silva, Jennifer Y Cui, David C Dalgarno, George P Lisi, Brenda M Rubenstein

Nat Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput prediction of protein conformational distributions with subsampled AlphaFold2.
Gabriel Monteiro da Silva, Jennifer Y Cui, David C Dalgarno, George P Lisi, Brenda M Rubenstein

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Relative Populations of Protein Conformations without a Physics Engine Using AlphaFold 2.
Gabriel Monteiro da Silva, Jennifer Y Cui, David C Dalgarno, George P Lisi, Brenda M Rubenstein

bioRxiv· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Relative Populations of Protein Conformations without a Physics Engine Using AlphaFold2.
Gabriel Monteiro da Silva, Jennifer Y Cui, David C Dalgarno, George P Lisi, Brenda M Rubenstein

ArXiv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Wei-Sheng Huang, Feng Li, Yongjin Gong, Yun Zhang, Willmen Youngsaye, David C Dalgarno

Bioorg Med Chem Lett· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery.
Stephan G Zech, Anna Kohlmann, Tianjun Zhou, Feng Li, Rachel M Squillace, David C Dalgarno

J Med Chem· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment growing and linking lead to novel nanomolar lactate dehydrogenase inhibitors.
Anna Kohlmann, Stephan G Zech, Feng Li, Tianjun Zhou, Rachel M Squillace, David C Dalgarno

J Med Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel rapamycin derivatives as low-level impurities in active pharmaceutical ingredients.
Stephan G Zech, Michael Carr, Qurish K Mohemmad, Narayana I Narasimhan, Christopher Murray, David C Dalgarno

J Antibiot (Tokyo)· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Mathew Thomas, Wei-Sheng Huang, David Wen, Xiaotian Zhu, Yihan Wang, David C Dalgarno

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, Yihan Wang, Mathew Thomas, David C Dalgarno

Chem Biol Drug Des· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Wei-Sheng Huang, Chester A Metcalf, Raji Sundaramoorthi, Yihan Wang, Dong Zou, David C Dalgarno

J Med Chem· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Tianjun Zhou, Lois Commodore, Wei-Sheng Huang, Yihan Wang, Tomi K Sawyer, David C Dalgarno

Chem Biol Drug Des· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Thomas O'Hare, William C Shakespeare, Xiaotian Zhu, Christopher A Eide, Victor M Rivera, David C Dalgarno

Cancer Cell· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
Wei-Sheng Huang, Xiaotian Zhu, Yihan Wang, Mohammad Azam, David Wen, David C Dalgarno

J Med Chem· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SRC inhibitors in metastatic bone disease.
Brendan F Boyce, Lianping Xing, Zhenqiang Yao, Teruhito Yamashita, William C Shakespeare, David C Dalgarno

Clin Cancer Res· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Liz Y Han, Charles N Landen, Jose G Trevino, Jyotsnabaran Halder, Yvonne G Lin, David C Dalgarno

Cancer Res· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Mohammad Azam, Valentina Nardi, William C Shakespeare, Chester A Metcalf, Regine S Bohacek, David C Dalgarno

Proc Natl Acad Sci U S A· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Future anti-catabolic therapeutic targets in bone disease.
Brendan F Boyce, Lianping Xing, Zhenqiang Yao, William C Shakespeare, Yihan Wang, David C Dalgarno

Ann N Y Acad Sci· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in F36VMpl-based in vivo selection among large animal models.
Robert E Richard, R Angelo De Claro, James Yan, Sylvia Chien, Horst Von Recum, David C Dalgarno

Mol Ther· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry.
Raji Sundaramoorthi, Noriyuki Kawahata, Michael G Yang, William C Shakespeare, Chester A Metcalf, David C Dalgarno

Biopolymers· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Raji Sundaramoorthi, William C Shakespeare, Terence P Keenan, Chester A Metcalf, Yihan Wang, David C Dalgarno

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Yihan Wang, Chester A Metcalf, William C Shakespeare, Raji Sundaramoorthi, Terence P Keenan, David C Dalgarno

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents.
Chi B Vu, George P Luke, Noriyuki Kawahata, William C Shakespeare, Yihan Wang, David C Dalgarno

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
William C Shakespeare, Chester A Metcalf, Yihan Wang, Raji Sundaramoorthi, Terence Keenan, David C Dalgarno

Curr Opin Drug Discov Devel· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis